Clinical trial
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
NCT00448266 · The Netherlands Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00448266 |
|---|---|
| Title | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD |
| Official title | Randomized Phase II/III Study of Intensified Alkylating Agent Chemotherapy With Peripheral Blood Progenitor Cell Support in the Preoperative Chemotherapy of Breast Tumors That Are Deficient for Homologous Recombination. |
| Lead sponsor | The Netherlands Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Intensified Cyclophophamide, Carboplatin and Thiotepa, dose dense adriamycine and cyclophosphamide |
| Enrollment | 12 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2011 |
| First posted | Mar 16, 2007 |
| Last update posted | Jan 22, 2021 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: